A recent clinical trial for a cannabidiol gel in Fragile X Syndrome did not meet its primary endpoint, largely due to a high placebo response. Learn more…

Explore the significant growth in cannabinoid clinical trials, with over 50 companies advancing novel therapies for conditions like Alzheimer's and chroni…

Avecho Biotechnology's CBD insomnia trial has surpassed its patient enrolment target, aiming for stronger statistical power. Learn about this crucial Phas…

A new guide, "Travelling with Medical Cannabis," has been published for UK patients to navigate complex rules. Learn how to ensure compliant medical canna…

Congressional efforts to advance or delay federal hemp amendments have stalled, impacting the future of hemp THC products. This report details legislative…

Discover the significant growth in cannabinoid clinical trials, with over 50 companies advancing new therapies for conditions like Alzheimer's and chronic…

U.S. cannabis rescheduling to Schedule III will accelerate medical research. This reclassification reduces regulatory barriers and opens new investment av…

Harmony Biosciences' cannabidiol gel ZYN002 did not meet its primary endpoint in a pivotal Fragile X Syndrome trial. Learn why the high placebo response i…

New research suggests daily CBD use may elevate liver enzymes. Clinicians should consider CBD use in routine medical screening for patients with liver con…

A Phase 1 clinical trial investigating a fixed-dose combination of CBD and hydroxychloroquine (IHL-675 A) for inflammatory conditions reports positive tol…